FDA Postpones Capitol Hill Meetings on User Fees, Pending White House Review

The FDA had to postpone meetings with Capitol Hill staff to discuss upcoming user fee legislation, after the Trump Administration directed agencies to halt correspondence with members of Congress.

A memo sent to the heads of HHS agencies and centers, including the FDA, said there would be no official communication with Congress before at least Feb. 3, unless specifically authorized by White House appointees.

It also states that no proposed or final regulation, notice or guidance document can be published until it has been reviewed by the acting secretary of HHS, Norris Cochran.